

HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Nuedexta

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:		Prescriber Name:			
HPP Member Number:		Fax:	Phone:		
Date of Birth:		Office Contact:			
Patient Primary Phone:		NPI:	PA PROMISe ID:		
Address:		Address:			
City, State ZIP:		City, State ZIP:			
Line of Business: ☐ Medicaid ☐ CHIP		Specialty Pharmacy (if applicable):			
Drug Name:		Strength:			
Quantity:		Refills:			
Directions:	.				
Diagnosis Code: Diagnosis: HPP's maximum approval time is 12 months but may be less depending on the drug.					
пер з тахітит аррго	var time is 12 mi	ontris but may be less depending	g on the drug.		
Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.					
Q1. Is this a renewal?	answer the for	lowing questions and sign.			
<u> </u>					
Yes	□ No				
Q2. Does patient have a diagnosis of pseudobulbar affect (PBA)?					
☐Yes		□ No			
Q3. Is the patient 18 years of age or older?					
Yes		□No			
Q4. Is the prescriber a neurologist or in consultation with a neurologist?					
Yes		☐ No			
Q5. Does the patient have any contraindications to Nuedexta (dextromethorphan hydrobromide and quinidine sulfate)?					
☐ Yes		□ No			
Q6. Does the patient profile show any contraindicated drug interactions (Risk X) with Nuedexta (dextromethorphan hydrobromide and quinidine sulfate)?					
☐ Yes		□ No			
Q7. Has any plan been made to address the contraindicated drug-drug interactions, such as discontinuation, dose reduction of interacting drugs, counseling patient of the risks associated with the potentially significant drug-drug interaction?					

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Nuedexta

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:			
☐ Yes	□ No			
Q8. For patients at risk of QT prolongation and torsades de pointes, will the patient have a baseline EKG and an EKG evaluation 3-4 hours after the first dose? (Patients at high risk of QT prolongation and torsades de pointes include recipients concomitantly taking any CYP3A4 inhibitors or medication which may prolong the QT interval and recipients with left ventricular hypertrophy or left ventricular dysfunction.)				
Yes	□ No			
Q9. Does the patient have potassium and magnesium levels within normal range?				
☐ Yes	□ No			
Q10. Does the patient have severe renal impairment (GFR less than 30)?				
☐ Yes	□ No			
Q11. Does the patient have any contraindications to Nuedexta (dextromethorphan hydrobromide and quinidine sulfate)?				
☐ Yes	□ No			
Q12. Does the patient profile show any contraindicated drug interactions (Risk X) with Nuedexta (dextromethorphan hydrobromide and quinidine sulfate)?				
☐ Yes	□ No			
Q13. Has any plan been made to address the contraindicated drug-drug interactions, such as discontinuation, dose reduction of interacting drugs, counseling patient of the risks associated with the potentially significant drug-drug interaction?				
☐Yes	□ No			
Q14. Does the provider submit the following laboratory tests? A. Repeat EKG if risk factors for arrhythmia change during the course of treatment with Nuedexta. (Risk factors include concomitant use of drugs associated with QT prolongation, electrolyte abnormalities (potassium and magnesium), bradycardia, and family history of QT abnormality.) B. Potassium and magnesium levels C. Complete blood count (CBC) D. Liver Function Tests (LFT) E. GFR				
☐ Yes	□ No			
Q15. Does the patient have documented improvement in PBA symptoms?				
☐ Yes	□ No			
Q16. Additional Information:				

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

Nuedexta

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Na	me:
Prescriber Signati	ure	Date

Updated for 2023